MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-026-04206-y

Медицинская библиотека · Nature medicine · 2026

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Petersen Kellen K, Milà-Alomà Marta, Li Yan, Du Lianlian, Xiong Chengjie, Tosun Duygu, Saef Benjamin, Saad Ziad S, Du-Cuny Lei, Coomaraswamy Janaky, Mordashova Yulia, Rubel Carrie E, Meyers Emily A, Shaw Leslie M, Dage Jeffrey L, Ashton Nicholas J, Zetterberg Henrik, Ferber Kyle, Triana-Baltzer Gallen, Baratta Michael, Rosenbaugh Erin G, Cruchaga Carlos, McDade Eric, Holtzman David M, Morris John C, Sabandal J Martin, Bateman Randall J, Bannon Anthony W, Potter William Z, Schindler Suzanne E, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team

СтатьяПеревод в очереди

Аннотация

Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer's disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R2 of 0.337-0.612) with a median absolute error of 3.0-3.7 years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

Для цитирования: Petersen Kellen K, Milà-Alomà Marta, Li Yan, Du Lianlian, Xiong Chengjie, Tosun Duygu, Saef Benjamin, Saad Ziad S, Du-Cuny Lei, Coomaraswamy Janaky, Mordashova Yulia, Rubel Carrie E, Meyers Emily A, Shaw Leslie M, Dage Jeffrey L, Ashton Nicholas J, Zetterberg Henrik, Ferber Kyle, Triana-Baltzer Gallen, Baratta Michael, Rosenbaugh Erin G, Cruchaga Carlos, McDade Eric, Holtzman David M, Morris John C, Sabandal J Martin, Bateman Randall J, Bannon Anthony W, Potter William Z, Schindler Suzanne E, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team. Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.. Nature medicine. 2026. DOI: 10.1038/s41591-026-04206-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.